LifeStance Health Group (NASDAQ:LFST) Major Shareholder Sells $144,890,858.34 in Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) major shareholder Tpg Gp A, Llc sold 13,643,207 shares of LifeStance Health Group stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $10.62, for a total transaction of $144,890,858.34. Following the sale, the insider directly owned 98,101,407 shares in the company, valued at approximately $1,041,836,942.34. The trade was a 12.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

LifeStance Health Group Trading Up 6.3%

LFST traded up $0.73 during trading hours on Wednesday, reaching $12.23. The company’s stock had a trading volume of 6,069,393 shares, compared to its average volume of 3,436,752. The stock has a market cap of $4.74 billion, a PE ratio of 94.08 and a beta of 1.14. LifeStance Health Group, Inc. has a fifty-two week low of $4.77 and a fifty-two week high of $12.43. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.38 and a quick ratio of 1.38. The business’s 50-day moving average is $10.10 and its 200-day moving average is $8.12.

LifeStance Health Group (NASDAQ:LFST) last posted its earnings results on Thursday, August 6th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.03. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.The company had revenue of $435.35 million during the quarter, compared to analysts’ expectations of $414.58 million. During the same quarter last year, the firm earned ($0.01) earnings per share. The firm’s quarterly revenue was up 26.1% compared to the same quarter last year. As a group, equities research analysts predict that LifeStance Health Group, Inc. will post 0.14 earnings per share for the current fiscal year.

Trending Headlines about LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Analyst upgrades support the rally: BTIG Research raised its price target from $15 to $16 while maintaining a Buy rating. Morgan Stanley also reaffirmed its Buy rating, reinforcing Wall Street confidence in LifeStance’s growth prospects. BTIG Raises LifeStance Price Target Morgan Stanley Reaffirms Buy Rating
• Positive Sentiment: Zacks upgraded LFST to Rank #2 (Buy): The upgrade reflects growing optimism about LifeStance’s earnings prospects and could attract additional near-term buying interest. LifeStance Health Upgraded to Buy
• Positive Sentiment: Shares reached a new 52-week high after the analyst upgrade. The move reflects strong recent momentum, supported by LifeStance’s latest quarterly performance, which included revenue growth of 26.1% year over year and earnings above analyst expectations. LifeStance Sets New 52-Week High
• Neutral Sentiment: LifeStance released survey results highlighting demand for integrated mental-health services during perimenopause and menopause. The findings support the company’s brand and potential service demand but do not represent a direct financial forecast or new contract. LifeStance Menopause Mental Health Survey
• Negative Sentiment: COO Lisa K. Miller sold 47,912 shares worth approximately $520,000, reducing her ownership by 14.55%. While insider sales can be motivated by personal financial planning, the transaction may create a modest sentiment headwind after the stock’s strong advance. SEC Insider Trading Filing

Institutional Investors Weigh In On LifeStance Health Group

Several institutional investors and hedge funds have recently modified their holdings of LFST. BlackRock Inc. acquired a new position in LifeStance Health Group in the 2nd quarter valued at about $389,293,000. Silversmith Partners I GP LLC purchased a new position in shares of LifeStance Health Group in the fourth quarter valued at approximately $100,842,000. Vanguard Group Inc. grew its holdings in shares of LifeStance Health Group by 21.1% in the fourth quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company’s stock valued at $124,608,000 after purchasing an additional 3,086,506 shares in the last quarter. Jennison Associates LLC increased its stake in LifeStance Health Group by 38.5% during the 1st quarter. Jennison Associates LLC now owns 10,228,801 shares of the company’s stock worth $65,157,000 after buying an additional 2,843,388 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in LifeStance Health Group by 62.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company’s stock worth $26,363,000 after buying an additional 1,839,465 shares in the last quarter. Hedge funds and other institutional investors own 85.50% of the company’s stock.

Wall Street Analysts Forecast Growth

LFST has been the topic of several research analyst reports. Canaccord Genuity Group boosted their price objective on shares of LifeStance Health Group from $11.00 to $13.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. The Goldman Sachs Group initiated coverage on shares of LifeStance Health Group in a research note on Friday, June 5th. They set a “neutral” rating and a $9.00 target price for the company. Barclays boosted their price target on shares of LifeStance Health Group from $9.00 to $13.00 and gave the company an “overweight” rating in a research note on Tuesday, July 14th. Zacks Research lowered shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Finally, JPMorgan Chase & Co. increased their price objective on shares of LifeStance Health Group from $8.00 to $9.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, LifeStance Health Group has an average rating of “Moderate Buy” and a consensus price target of $11.62.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.